

Sara Massironi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8719736/publications.pdf>

Version: 2024-02-01

97
papers

3,937
citations

147726
31
h-index

133188
59
g-index

97
all docs

97
docs citations

97
times ranked

5166
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. <i>Endocrine</i> , 2022, 75, 942-948.	1.1	5
2	Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 713.	1.0	6
3	Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study. <i>Cells</i> , 2022, 11, 692.	1.8	8
4	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2022, 5, e220290.	2.8	21
5	Clinical and Endoscopic Outcomes in COVID-19 Patients With Gastrointestinal Bleeding. , 2022, 1, 487-499.		9
6	Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. <i>World Journal of Gastroenterology</i> , 2022, 28, 1123-1138.	1.4	16
7	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2658.	1.0	3
8	Systematic review of pancreatic involvement in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1478-1491.	1.9	18
9	Letter: pancreatic involvement in inflammatory bowel disease authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 371-371.	1.9	1
10	The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. <i>Journal of Clinical Medicine</i> , 2022, 11, 3794.	1.0	12
11	Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. <i>World Journal of Gastroenterology</i> , 2022, 28, 3258-3273.	1.4	13
12	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	1.8	38
13	Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs). , 2021, , 55-74.		0
14	Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. <i>Pharmaceuticals</i> , 2021, 14, 539.	1.7	7
15	Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey. <i>Digestive and Liver Disease</i> , 2021, 53, 682-688.	0.4	30
16	Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 702-716.	0.8	13
17	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
18	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. <i>World Journal of Gastroenterology</i> , 2021, 27, 5890-5907.	1.4	26

#	ARTICLE	IF	CITATIONS
19	Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. <i>World Journal of Gastroenterology</i> , 2021, 27, 5520-5535.	1.4	10
20	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
21	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32
22	Understanding short bowel syndrome: Current status and future perspectives. <i>Digestive and Liver Disease</i> , 2020, 52, 253-261.	0.4	82
23	Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2020, 8, 140-147.	1.6	17
24	Reply. <i>Pancreas</i> , 2020, 49, e81-e82.	0.5	0
25	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020, 35, 141-148.	0.8	14
26	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e138-e139.	0.9	8
27	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \leq 2 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 598438.	1.2	33
28	Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2375-2377.	2.4	35
29	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	1.8	279
30	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	1.9	27
31	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1111-1117.	0.6	1
32	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 1456-1460.	0.4	32
33	Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1992.	1.0	25
34	Deficiency of micronutrients in patients affected by chronic atrophic autoimmune gastritis: A single-institution observational study. <i>Digestive and Liver Disease</i> , 2019, 51, 505-509.	0.4	12
35	The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. <i>Autoimmunity Reviews</i> , 2019, 18, 215-222.	2.5	94
36	Neuroendocrine neoplasms of rectum: A management update. <i>Cancer Treatment Reviews</i> , 2018, 66, 45-55.	3.4	52

#	ARTICLE	IF	CITATIONS
37	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
38	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
39	A case of positive 68 Ga-DOTATOC-PET/CT pancreatic heterotopia mimicking an intestinal neuroendocrine tumor. <i>Clinical Imaging</i> , 2018, 49, 156-158.	0.8	3
40	Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. <i>Digestive and Liver Disease</i> , 2018, 50, 6-14.	0.4	40
41	Relevance of vitamin D deficiency in patients with chronic autoimmune atrophic gastritis: a prospective study. <i>BMC Gastroenterology</i> , 2018, 18, 172.	0.8	20
42	Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2018, 47, 1249-1255.	0.5	35
43	Intraductal papillary mucinous neoplasms of the pancreas: a clinical challenge. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1123-1133.	1.4	13
44	Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms. <i>Pancreatology</i> , 2018, 18, 792-798.	0.5	7
45	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
46	Effects of a Gluten-Containing Meal on Gastric Emptying and Gallbladder Contraction. <i>Nutrients</i> , 2018, 10, 910.	1.7	5
47	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3200-3206.	0.7	39
48	Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 835-842.	0.6	29
49	ASO Author Reflections: Heterogeneity of Duodenal Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 858-859.	0.7	1
50	Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018, 13, e0196858.	1.1	14
51	Impact of Vitamin D on the Clinical Outcome of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Report on a Series from a Single Institute. <i>Neuroendocrinology</i> , 2017, 105, 403-411.	1.2	21
52	Endoscopic techniques to detect small bowel neuroendocrine tumors: A literature review. <i>United European Gastroenterology Journal</i> , 2017, 5, 5-12.	1.6	27
53	Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. <i>Digestive and Liver Disease</i> , 2017, 49, 978-983.	0.4	12
54	IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. <i>Endocrine</i> , 2017, 58, 360-367.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome. <i>Gastroenterology</i> , 2017, 152, S670.	0.6	0
56	Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms. <i>Gastroenterology</i> , 2017, 152, S669.	0.6	0
57	Small Bowel Ultrasound beyond Inflammatory Bowel Disease: An Updated Review of the Recent Literature. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 1741-1752.	0.7	12
58	Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. <i>World Journal of Gastroenterology</i> , 2017, 23, 2640.	1.4	21
59	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 18, 419-449.	0.6	4
60	Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: A review. <i>World Journal of Gastroenterology</i> , 2017, 23, 563.	1.4	66
61	Primary sclerosing cholangitis associated with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 123-131.	0.8	51
62	Chromogranin A and other enteroendocrine markers in inflammatory bowel disease. <i>Neuropeptides</i> , 2016, 58, 127-134.	0.9	23
63	Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 513-523.	0.6	22
64	A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival. <i>Oncotarget</i> , 2016, 7, 18978-18983.	0.8	21
65	Ultrasound elastographic techniques in focal liver lesions. <i>World Journal of Gastroenterology</i> , 2016, 22, 2647.	1.4	21
66	The Role of Ultrasound Elasticity Imaging in Predicting Ileal Fibrosis in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2605-2612.	0.9	73
67	Hepatic Hemangioma in Celiac Patients: Data from a Large Consecutive Series. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	9
68	Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. <i>Digestive and Liver Disease</i> , 2015, 47, 819-825.	0.4	64
69	Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1397-1403.	0.6	45
70	Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. <i>Digestive and Liver Disease</i> , 2015, 47, 978-983.	0.4	33
71	Somatostatin analogs for gastric carcinoids: For many, but not all. <i>World Journal of Gastroenterology</i> , 2015, 21, 6785-6793.	1.4	14
72	An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: An unusual association and review of the literature. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 443.	0.3	6

#	ARTICLE	IF	CITATIONS
73	Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. <i>BMC Gastroenterology</i> , 2014, 14, 110.	0.8	8
74	Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution. <i>Neuroendocrinology</i> , 2014, 100, 240-249.	1.2	72
75	Therapy for metastatic pancreatic neuroendocrine tumors. <i>Annals of Translational Medicine</i> , 2014, 2, 8.	0.7	29
76	Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?. <i>Anticancer Research</i> , 2014, 34, 7361-5.	0.5	3
77	Nutritional deficiencies in inflammatory bowel disease: Therapeutic approaches. <i>Clinical Nutrition</i> , 2013, 32, 904-910.	2.3	126
78	Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. <i>European Journal of Endocrinology</i> , 2013, 168, 755-761.	1.9	30
79	Transient elastography in patients with celiac disease: A noninvasive method to detect liver involvement associated with celiac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 640-648.	0.6	4
80	Unusually aggressive type 1 gastric carcinoid. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 589-593.	0.8	31
81	Treatment of Liver Metastases in Patients with Digestive Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1981-1992.	0.9	13
82	Referrals for bowel ultrasound in clinical practice: A survey in 12 nationwide centres in Italy. <i>Digestive and Liver Disease</i> , 2011, 43, 165-168.	0.4	5
83	Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 180-184.	0.8	47
84	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. <i>Hepatology</i> , 2010, 52, 1723-1730.	3.6	67
85	Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. <i>American Journal of Hematology</i> , 2010, 85, 564-568.	2.0	40
86	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. <i>Gut</i> , 2010, 59, 638-644.	6.1	358
87	Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2010, 42, 635-641.	0.4	23
88	Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors. <i>American Journal of Gastroenterology</i> , 2010, 105, 2072-2078.	0.2	57
89	“Pseudotumoral” hepatic pattern in acute alcoholic hepatitis: A case report. <i>World Journal of Gastroenterology</i> , 2009, 15, 4070.	1.4	1
90	Plasma chromogranin a in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 867-871.	0.9	98

#	ARTICLE	IF	CITATIONS
91	Sporadic and MEN1-Related Primary Hyperparathyroidism: Differences in Clinical Expression and Severity. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1404-1410.	3.1	115
92	Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2009, 41, 31-35.	0.4	39
93	Gastric carcinoids: Between underestimation and overtreatment. <i>World Journal of Gastroenterology</i> , 2009, 15, 2177.	1.4	43
94	Neuroendocrine tumors of the gastro-entero-pancreatic system. <i>World Journal of Gastroenterology</i> , 2008, 14, 5377.	1.4	152
95	Role of US in Detection of Crohn Disease: Meta-Analysis. <i>Radiology</i> , 2005, 236, 95-101.	3.6	279
96	Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2005, 11, 7318.	1.4	27
97	Early effects of total paracentesis and albumin infusion on muscle sympathetic nerve activity in cirrhotic patients with tense ascites. <i>Journal of Hepatology</i> , 1999, 30, 95-100.	1.8	11